SCYNEXIS Secures Up to $213.9 Million BARDA Contract for SCY-247 Development

Filing content

SCYNEXIS has entered into a contract with BARDA for up to $213.9 million in non-dilutive funding to advance SCY-247 for invasive candidiasis. The initial base period provides approximately $18.5 million to support a Phase 2 study.